RDNT Earnings

RDNT reported its earnings on 2026-03-02, showcasing a revenue of 547.71M against an estimate of 515.37M, resulting in a 6.28% surprise. The EPS was 0.23, surpassing the expected 0.19 by 21.05%. The stock experienced a 7.75% price change on the earnings day and a -4.5% change over the next five days, reflecting market reactions to the results.

Following RDNT's earnings announcement on 2026-03-02, the stock price moved by 7.75% on the day of the release. Over the subsequent five days, it saw a -4.5% change. Historically, RDNT's stock price tends to shift by an average of -4.58% in the 10 days leading up to earnings and 3.27% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate RDNT's annual revenue to reach 522.35M, while the EPS is projected at -0.06. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between RDNT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RDNT's stock price typically moves by -4.58% in the 10 days before its earnings and 3.27% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.06 and revenue of 522.35M.

The earnings call summary indicates positive financial performance with increased revenue, net income, and EBITDA, despite higher operating expenses. The acquisition of Gleamer aligns with RadNet's strategic focus on AI-driven radiology, potentially boosting future growth. Risks like integration challenges and reimbursement issues were noted, but the raised guidance for 2025 and Medicare reimbursement uplift for 2026 offset these concerns. The lack of shareholder return programs is neutral, but the strategic investments and strong financial metrics suggest a positive stock price movement.